Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Effects of Transcranial Photobiomodulation in ADHD

NCT: NCT07203092 · RECRUITING

NCT IDNCT07203092
StatusRECRUITING
Start Date2025-09-01
Completion2027-12

Brief Summary

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Frequently Asked Questions

What is Effects of Transcranial Photobiomodulation in ADHD?

Effects of Transcranial Photobiomodulation in ADHD is a clinical trial registered under NCT07203092. Current status: RECRUITING.

What is the status of NCT07203092?

The current status of NCT07203092 (Effects of Transcranial Photobiomodulation in ADHD) is: RECRUITING.

When did Effects of Transcranial Photobiomodulation in ADHD start?

Effects of Transcranial Photobiomodulation in ADHD started on 2025-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.